Although several studies have reported increased FABP4 expression in liver tissue from patients with insulin resistance, its expression during liver carcinogenesis and the potential regulatory effect of metformin, the most common antidiabetic treatment used in this context, have not been previously studied [28, 29]. The gene discussed is FABP4; the disease is Insulin resistance.